The Claim
In older adults with coronary artery disease undergoing cardiac rehabilitation, twelve weeks of daily low-dose rapamycin (0.5–1.0 mg) was associated with an increase in serum MMP-3 levels from 23.5 to 26 ng/ml, though the clinical significance of this change is uncertain due to the dual roles of MMP-3 in tissue remodeling and inflammation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a low dose of a drug called rapamycin every day for three months might have increased a protein in the blood linked to healing and inflammation in older people with heart disease — but we’re not sure what that really means for their health.
See the scientific wording
Twelve weeks of daily low-dose rapamycin (0.5–1.0 mg) in older adults with coronary artery disease undergoing cardiac rehabilitation was associated with increased serum MMP-3 levels (from 23.5 to 26 ng/ml), a change whose clinical significance remains unclear due to mixed roles of MMP-3 in tissue remodeling and inflammation.
What the research says
1 studyThe study gave older adults with heart disease a low dose of rapamycin for 12 weeks and found their MMP-3 levels went up, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.